Checkpoint blockade for the treatment of advanced melanoma Journal Article
| Authors: | Callahan, M. K.; Flaherty, C. R.; Postow, M. A. |
| Article Title: | Checkpoint blockade for the treatment of advanced melanoma |
| Abstract: | Immunotherapy with immune checkpoint inhibition has been improving the outcomes of patients with many different types of malignancies. Immune checkpoint inhibition has been most extensively studied in patients with advanced melanoma and there are three FDA approved antibodies already widely used in clinical practice (ipilimumab, nivolumab, and pembrolizumab). In this chapter, we review the mechanistic basis behind the development of immune checkpoint blocking antibodies. We then discuss specifics regarding each agent, unique clinical considerations in treating patients with this approach, and future directions, including combination strategies. This chapter is focused on melanoma, but the principles related to this immunotherapy approach are applicable to patients with many types of malignancies. © Springer International Publishing Switzerland 2016. |
| Keywords: | cancer survival; treatment response; unclassified drug; overall survival; drug tolerability; advanced cancer; cancer combination chemotherapy; dose response; drug dose comparison; drug efficacy; drug safety; drug withdrawal; drug approval; cancer radiotherapy; outcome assessment; cytotoxic t lymphocyte antigen 4 antibody; dacarbazine; ipilimumab; cancer immunotherapy; melanoma; neuropathy; food and drug administration; tumor marker; pneumonia; immunotherapy; pancreatitis; clinical effectiveness; cytopenia; uveitis; myopathy; metastatic melanoma; randomized controlled trial (topic); phase 2 clinical trial (topic); phase 3 clinical trial (topic); phase 1 clinical trial (topic); conjunctivitis; receptor antibody; nephritis; nivolumab; immune checkpoint; human; priority journal; immune-related adverse events; immune-related response criteria; programmed cell death 1 receptor antibody |
| Journal Title: | Cancer Treatment and Research |
| Volume: | 167 |
| ISSN: | 0927-3042 |
| Publisher: | Springer |
| Date Published: | 2016-01-01 |
| Start Page: | 231 |
| End Page: | 250 |
| Language: | English |
| DOI: | 10.1007/978-3-319-22539-5_9 |
| PROVIDER: | scopus |
| PUBMED: | 26601865 |
| DOI/URL: | |
| Notes: | Chapter 9 in "Melanoma" (ISBN: 978-3-319-22538-8) -- Export Date: 7 January 2016 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work